First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours

Debbie Robbrecht, Christiane Jungels, Morten Mau‐Sørensen, Iben Spanggaard, Ferry A.L.M. Eskens, Signe Øien Fretland, Tormod Kyrre Guren, Philippe Aftimos, David Liberg, Christer Svedman, Lars Thorsson, Neeltje Steeghs, Ahmad Awada